Novel, On-Off Switchable, Drug Delivery Vehicles, FabricationTechniques and Applications Thereof
University researchers have developed a nanotechnology for innovative new drug delivery capability, i.e., new nanotechnology-based, magnetically or ultrasonically switchable drug delivery vehicles with easy, remotely on-off switchable release capability. Three types of embodiments of the actuate-able, drug-delivery biomaterials have been disclosed. The invention addresses the spurious assumption of constant rate drug release being optimal. The drug delivery system for constant release can not meet the cyclic or irregular drug requirement in human body. Therefore, this invention addresses the need to challenge and create a new regime of on-demand, drug release techniques with a targeting and timing strategy.
Patent Number: US20100303716A1
Application Number: US2010741590A
Inventor: Jin, Sungho | Oh, Seunghan | Brammer, Karla | Kong, Seong
Priority Date: 15 Nov 2007
Priority Number: US20100303716A1
Application Date: 9 Aug 2010
Publication Date: 2 Dec 2010
IPC Current: A61F000200 | A61K0031175 | A61K0031337 | A61K003156 | A61K0031573 | A61K0031715 | A61K003822 | A61K003828 | A61K0039395 | A61K004800 | A61K005100 | A61P002500
US Class: 42400111 | 4241301 | 4241331 | 424422 | 5140059 | 5140097 | 514044R | 514054 | 514169 | 514180 | 514449 | 514589
Assignee Applicant: The Regents of the University of California
Title: SWITCHABLE NANO-VEHICLE DELIVERY SYSTEMS, AND METHODS FOR MAKING AND USING THEM
Usefulness: SWITCHABLE NANO-VEHICLE DELIVERY SYSTEMS, AND METHODS FOR MAKING AND USING THEM
Summary: The nanodevice is useful for switchable or controlled on-off release of a compound in vivo or in situ for treating, preventing or ameliorating a disease selected from inherited hemophilia, Factor VIII or Factor IX deficiency, deficient or defective clotting factor or blood-coagulation, liver function loss because of an infectious disease, hepatitis, cancer, poisoning, or toxicity or poisoning by insecticides or nerve gas, or α 1 anti-trypsin deficiency in an individual of a hereditary disease, a liver disease, or neonatal jaundice and/or emphysema, detoxification of blood in patients or an individual having a hereditary disease, a liver disease or OTC deficiency, or renal insufficiency or uremic poisoning (all claimed).
Novelty: Nanodevice for switchable or controlled on-off release of compound for treating disease e.g. inherited hemophilia, comprises hollow nanospheres, nano-reservoir array with valves and/or re-entrant nano-depot array with valves
診斷/治療
其他疾病
8968699
Tech ID/UC Case 19784/2008-144-0 Related Cases 2008-144-0
美國
